Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × GATA2 Deficiency × Plasma cell × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Other hematologic neoplasm 1

Conditions

Multiple Myeloma 400 Neoplasms, Plasma Cell 69 Recurrence 52 Lymphoma 49 Lymphoma, Non-Hodgkin 46 Leukemia 41 Hodgkin Disease 40 Leukemia, Myeloid, Acute 38 Myelodysplastic Syndromes 34 Leukemia, Lymphocytic, Chronic, B-Cell 32 Precursor Cell Lymphoblastic Leukemia-Lymphoma 30 Lymphoma, Large B-Cell, Diffuse 27 Lymphoma, Mantle-Cell 26 Lymphoma, Follicular 26 Hematologic Neoplasms 22 Burkitt Lymphoma 22 Immunoglobulin Light-chain Amyloidosis 21 Myeloproliferative Disorders 20 Lymphoma, B-Cell, Marginal Zone 20 Lymphoma, Large-Cell, Immunoblastic 17 Waldenstrom Macroglobulinemia 16 Neoplasms 15 Lymphoma, T-Cell, Cutaneous 15 Leukemia, Myelomonocytic, Chronic 14 Lymphoma, Large-Cell, Anaplastic 13 Sezary Syndrome 12 Mycosis Fungoides 12 Leukemia, Myeloid, Accelerated Phase 12 Blast Crisis 12 Primary Myelofibrosis 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03018405 2019-09-19

THINK

Celyad Oncology SA

Phase 1/2 Unknown

GATA2 Deficiency, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡